Disease · MONDO_0000386
digestive system neuroendocrine tumor, grade 1/2
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. digestive system neuroendocrine tumor, grade 1/2. Diseases, record MONDO_0000386. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000386
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs33
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Protein | Phase 3 | ClinicalTrials.gov | 15 | 15 | 11 | Drugs and targets |
| OCTREOTIDE | CHEMBL1680 | Protein | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| LANREOTIDE | CHEMBL1201185 | Protein | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| LUTETIUM LU 177 ZADAVOTIDE GURAXETAN | CHEMBL5314936 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | CHEMBL4594406 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| LUTETIUM LU177 EDOTREOTIDE | CHEMBL5095425 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| LUTETIUM OXODOTREOTIDE | CHEMBL4302409 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACTINIUM AC 225 DOTATATE | CHEMBL6068416 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 33
See all 33 drugsTargets60
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 5 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 5 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 5 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| SSTR2 | Somatostatin receptor | 4 | Somatostatin receptor 2 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 3 | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 4 | Somatostatin receptor 5 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 3 | https://conductscience.org/library/genes/6755 | Drugs and targets |
| CSF1R | Macrophage colony-stimulating factor 1 receptor | 3 | Macrophage colony stimulating factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/1436 | Drugs and targets |
| RET | Proto-oncogene tyrosine-protein kinase receptor Ret | 3 | Tyrosine-protein kinase receptor RET inhibitor | Phase 2 | https://conductscience.org/library/genes/5979 | Drugs and targets |
1 to 10 of 60
See all 60 targetsTrials41
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03972488 | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET | Phase 3 | 226 | 2024-10-10 | Gastro-enteropancreatic Neuroendocrine Tumor | LUTETIUM OXODOTREOTIDE LU-177, OCTREOTIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02678780 | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors | Phase 2 | 123 | 2025-07-24 | Neuroendocrine Tumors | LENVATINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | Phase 2 | 93 | 2025-06-19 | Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma | ATEZOLIZUMAB, CABOZANTINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Phase 1/2 | 89 | 2021-12-14 | Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma | NENDRATAREOTIDE UZATANSINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04852679 | Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs | Phase 3 | 43 | 2024-10-01 | Gastroenteropancreatic Neuroendocrine Tumor | LANREOTIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00434109 | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | Phase 2 | 39 | 2012-09-07 | Neuroendocrine Tumor, Islet Cell Tumor | SUNITINIB MALATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04234568 | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | Phase 1 | 31 | 2025-11-03 | Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor | LUTETIUM OXODOTREOTIDE LU-177, TRIAPINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02132468 | A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers | Phase 2 | 18 | 2017-10-19 | Neuroendocrine Tumors | FOSBRETABULIN TROMETHAMINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | Phase 2 | 11 | 2024-11-27 | Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma | LUTETIUM OXODOTREOTIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02859064 | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | Phase 2 | 6 | 2023-07-27 | Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors | LANREOTIDE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 41
See all 41 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Neuroendocrine Tumors of the Pancreas vs Neuroendocrine Tumors of Gastrointestinal Tract: deaths from any cause | 21 of 55 | 29 of 56 | 111 | NCT02678780 | Trial comparisons |
| Neuroendocrine Tumors of the Pancreas vs Neuroendocrine Tumors of Gastrointestinal Tract: serious adverse events | 23 of 55 | 24 of 56 | 111 | NCT02678780 | Trial comparisons |
| Main Intervention Period: Lanreotide Autogel 120 mg vs Independent Injection Period: Lanreotide Autogel 120 mg: deaths from any cause | 2 of 43 | 0 of 5 | 48 | NCT04852679 | Trial comparisons |
| Main Intervention Period: Lanreotide Autogel 120 mg vs Independent Injection Period: Lanreotide Autogel 120 mg: serious adverse events | 4 of 43 | 0 of 5 | 48 | NCT04852679 | Trial comparisons |
| GEP-NET vs PPGL: Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration | 4 of 4 | 6 of 7 | 11 | NCT04711135 | Trial comparisons |
Papers from its trials35
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000386
GET https://conductscience.org/api/diseases/v1/MONDO_0000386/drugs?page=2